Alzamend Neuro, Inc.

Alzamend Neuro, Inc. reported a net loss of $2.2 million for Q3 2026, consistent with its loss from operations, as the company generated no revenue during the period. Operating expenses totaled $2.2 million, comprising $1.3 million in research and development and $919,000 in general and administrative costs. The company ended the quarter with $2.7 million in cash and total assets of $4.0 million, while total liabilities stood at $1.9 million, resulting in stockholders' equity of $2.2 million. Cash flow from operations was negative $5.3 million, partially offset by $4.0 million in net cash provided by financing activities from stock issuances. The company's basic and diluted net loss per common share was $1.00, based on 3.8 million weighted average common shares outstanding.

Key Takeaways